Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab Preclinical Data under ...
Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A research team led by CiRA Professor Haruhisa Inoue has developed a cellular dissection of polygenicity (CDiP) technology, which enables the reconstruction of the clinical conditions of Alzheimer's ...
The Shin Kaneko laboratory at CiRA has developed a method to generate CAR-T cells from iPS cells (iCAR-T cells) that possess vastly improved anti-tumor activity in a mouse model of solid tumors. In ...
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients ...
SAN DIEGO, March 28, 2022 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem ...
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results